HMGB1 and neoplasm: Anthracyclin or oxaliplatin treatment induced (i) translocation of calreticulin (CRT) to the tumor cell surface, (ii) release of the TLR4 ligand high mobility group box 1 (HMGB1) protein, and (iii) release of ATP by dying tumor cells, all of which act in concert to promote IL-1β secretion by DCs and ultimately result in a protective tumor-specific CD8+ T-cell response [119].